C4 Therapeutics Corp (CCCC) - Market Cap to Net Income Ratio

C4 Therapeutics, Inc. (CCCC) is developing a protein degradation system to combat neoplasms, leveraging cutting-edge science and alliances with industry behemoths. However, high research costs and uncertainty surrounding primary tests create certain risks. This market valuation chart reflects a value of -3.90, while current quotes already price in development complexities, and capital inflows from global partners provide a tangible impulse.

CCCC c4therapeutics.com: Price to Earnings Ratio in the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for C4 Therapeutics Corp (CCCC)

- market price and analyst price targets:

Market Price C4 Therapeutics|CCCC - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization C4 Therapeutics Corp|CCCC - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Net Asset Value per Share C4 Therapeutics|CCCC - Company Net Assets|Market Value to Book Value c4therapeutics.com|CCCC - Cumulative Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

CCCC - Net Income|Future Net Profit C4 Therapeutics, Inc.|CCCC - P/E Multiple|Projected Price to Earnings Ratio C4 Tx|CCCC - PEG Multiple|Enterprise Value to Operating Income Before Depreciation C4 Therapeutics Corp|CCCC - Operating profit before deduction of amortization|Earnings per share for the trailing year C4 Therapeutics|CCCC - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months c4therapeutics.com|CCCC - Earnings growth in current year|Expected earnings per share trend next year C4 Therapeutics, Inc.

- issuer revenue and sales details:

CCCC - Revenue and Sales Volume|Company Expected Sales Volume C4 Therapeutics Inc|CCCC - Price-to-Revenue Ratio|Forward Price to Sales C4 Therapeutics Inc|CCCC - Sales Growth YoY (TTM)

Comprehensive company analysis:C4 Therapeutics - CCCC

The asset-light outsourcing model of C4 Therapeutics, Inc. (CCCC) defines the specific relationship between the stock price and the company's earnings. This ratio compares the asset's market value to net income, measuring the payback period for investments. The calculation is based on dividing the current quote by earnings per share, reflecting market expectations for drug development efficiency. Ignoring this context creates a risk of capital freeze.

Key competitors

Market Cap to Earnings Genmab GMAB|P/E Multiple EXEL|Nuvalent, Inc. (NUVL) - Market Cap to Net Income Ratio|Kymera Therapeutics, Inc. - Price to Earnings Ratio|IDEAYA Biosciences, Inc. (IDYA) - Market Cap to Earnings|ELVN: Price to Earnings Ratio|Company Value to Net Income ORIC (ORIC Pharma)|RLAY (Relay Therapeutics, Inc.) - Price to Earnings Ratio|NRIX: Market Price to Net Income Ratio|TYRA (Tyra Corp) - P/E Multiple|P/E Multiple verastem.com|Price to Earnings Ratio Monte Rosa Therapeutics, Inc. (GLUE)|CGEM (Cullinan Therapeutics, Inc.) - Company Value to Net Income|P/E Multiple IMRX (Immuneering Corp)|Market Cap to Net Income Ratio Black Diamond Therapeutics Inc.|Repare Therapeutics, Inc. - P/E Multiple|Market Cap to Earnings PMV Pharmaceuticals, Inc.|KPTI (karyopharm.com) - Price to Earnings Ratio|PPCB: Market Price to Net Income Ratio|BGMS (cyclacel.com) - P/E Multiple|Market Cap to Earnings Aadi Bioscience AADI|P/E Multiple ALRN|Blueprint Medicines Corp - Price to Earnings Multiple|GlycoMimetics, Inc. - Price to Earnings Ratio|Company Value to Net Income SWTX